文献速递卫生政策与健康促进免疫规划传染病防控与疫情报告

印度尼西亚SARS-CoV-2加强接种的社会价值

The societal value of SARS-CoV-2 booster vaccination in Indonesia.
PubMed 文献 · Vaccine · 2023-02-01

加强接种每剂价值在首年为2500美元(1400-4100美元)至2800美元(1700-4600美元),取决于生命年估值。结论认为加强接种的社会效益巨大,其价值很大程度在于减少对昂贵非药物干预的需求,并建议将成本最小化作为政策决策和疫苗估值工具。

要点

  • 模拟显示加强接种可避免大量面对面教育损失和经济活动损失。
  • 加强接种每剂社会价值首年为2500-2800美元,取决于生命年估值。
  • 疫苗价值很大程度在于减少对 costly 非药物干预的需求。

核心结论

  • 加强接种的社会效益巨大,其价值很大程度在于减少对昂贵非药物干预的需求。
  • 作者建议将成本最小化作为政策决策和疫苗估值的工具,综合考虑所有社会经济成本,而非仅避免死亡。

研究设计与样本

  • 成本包括生命损失、经济停摆和教育损失,每个情景选择成本最小化的非药物干预。

主要发现

  • 加强接种每剂价值在首年为2500美元(1400-4100美元)至2800美元(1700-4600美元),取决于生命年估值。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate the expected socio-economic value of booster vaccination in terms of averted deaths and averted closures of businesses and schools using simulation modelling. METHODS: The value of booster vaccination in Indonesia is estimated by comparing simulated societal costs under a twelve-month, 187-million-dose Moderna booster vaccination campaign to costs without boosters. The costs of an epidemic and its mitigation consist of lost lives, economic closures and lost education; cost-minimising non-pharmaceutical mitigation is chosen for each scenario. RESULTS: The cost-minimising non-pharmaceutical mitigation depends on the availability of vaccines: the differences between the two scenarios are 14 to 19 million years of in-person education and $153 to $204 billion in economic activity. The value of the booster campaign ranges from $2,500 ($1,400-$4,100) to $2,800 ($1,700-$4,600) per dose in the first year, depending on life-year valuations. CONCLUSIONS: The societal benefits of booster vaccination are substantial. Much of the value of vaccination resides in the reduced need for costly non-pharmaceutical mitigation. We propose cost minimisation as a tool for policy decision-making and valuation of vaccination, taking into account all socio-economic costs, and not averted deaths alone.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Johnson R, Djaafara B, Haw D, et al. The societal value of SARS-CoV-2 booster vaccination in Indonesia. Vaccine. 2023. PMID: 36781331. doi:10.1016/j.vaccine.2023.01.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。